NEW YORK, Sept. 15, 2023 /PRNewswire/ — Hoth Therapeutics, Inc. (NASDAQ: HOTH) (“Hoth” or the “Company”), a patient-focused biopharmaceutical company, today announced the closing of its previously announced registered direct offering, priced at-the-market under Nasdaq rules, for the…